What is the equivalent of lisinopril (Angiotensin-Converting Enzyme Inhibitor)-HCTZ (Hydrochlorothiazide) 20-12.5 in losartan (Angiotensin II Receptor Antagonist) combined?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Losartan-HCTZ Equivalent to Lisinopril-HCTZ 20-12.5

The equivalent combination to lisinopril-HCTZ 20-12.5 mg is losartan-HCTZ 50-12.5 mg, which is the standard fixed-dose combination available and listed in major hypertension guidelines. 1

Rationale for Dose Equivalence

The JNC 7 guidelines explicitly list the available fixed-dose combinations for both ACE inhibitors and ARBs with hydrochlorothiazide 1:

  • Lisinopril-HCTZ combinations: 10/12.5,20/12.5, and 20/25 mg
  • Losartan-HCTZ combinations: 50/12.5 and 100/25 mg

The losartan 50 mg dose combined with HCTZ 12.5 mg represents the standard starting combination that provides comparable blood pressure lowering to lisinopril 20 mg with HCTZ 12.5 mg. 1, 2

Clinical Evidence Supporting Equivalence

Blood Pressure Lowering Efficacy

  • Both ACE inhibitors and ARBs demonstrate similar cardiovascular outcome benefits when combined with thiazide diuretics, with the primary benefit deriving from blood pressure reduction itself 1

  • Losartan-HCTZ 50/12.5 mg has been shown to effectively lower blood pressure in patients with mild to moderate hypertension, with mean reductions of approximately 16-18 mmHg systolic and 12-18 mmHg diastolic 2, 3

  • Lisinopril-HCTZ 20/12.5 mg produces comparable blood pressure reductions, with mean decreases of approximately 16-24 mmHg systolic and 12-18 mmHg diastolic 4, 5

Cardiovascular Outcomes

  • The LIFE study demonstrated that losartan-based therapy (which included losartan-HCTZ combinations) reduced cardiovascular morbidity and mortality compared to atenolol-based therapy, primarily through stroke risk reduction 2

  • ACE inhibitors and ARBs show equivalent efficacy in reducing major cardiovascular events when blood pressure is controlled to similar levels 1

Important Clinical Considerations

When Higher Doses May Be Needed

If blood pressure control is inadequate on losartan-HCTZ 50/12.5 mg, the dose can be increased to losartan-HCTZ 100/25 mg. 1, 2 The HEAAL trial demonstrated that losartan 150 mg daily was superior to 50 mg daily, supporting the use of higher ARB doses when needed 1

Specific Patient Populations

  • Diabetes with nephropathy: Both ACE inhibitors and ARBs provide renoprotective benefits; ARBs may be preferred if ACE inhibitor intolerance (particularly cough) is present 1

  • Heart failure with reduced ejection fraction: While both classes are beneficial, specific dosing targets from heart failure trials should guide therapy 1

  • Elderly patients with isolated systolic hypertension: Both combinations are effective, with thiazide diuretics providing the primary benefit 1

Common Pitfalls to Avoid

  • Do not assume 1:1 mg equivalence between lisinopril and losartan—the standard fixed-dose combinations reflect clinically validated dosing ratios 1

  • Monitor potassium levels when switching between these combinations, as both ACE inhibitors and ARBs can cause hyperkalemia, particularly in patients with chronic kidney disease 1

  • Assess for angioedema history: Patients with ACE inhibitor-induced angioedema can receive an ARB, but should wait 6 weeks after ACE inhibitor discontinuation before starting the ARB 1

  • Verify adequate HCTZ dosing: The 12.5 mg HCTZ dose is appropriate and minimizes metabolic side effects compared to higher doses 1, 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.